Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1994-12-27
1997-06-03
Hutzell, Paula K.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303882, 5303883, 5303884, 5303888, 53038823, 53038822, C07K 1618, C07K 1646
Patent
active
056356005
ABSTRACT:
Monoclonal antibodies which react specifically to Fc receptor of human effector cells IgG are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4676980 (1987-06-01), Segal et al.
patent: 4954617 (1990-09-01), Fanger et al.
Clark et al. (1990) in Bispecific Antibodies and Targeted Cellular Cytoxicity (Romet-Lemonne et al., eds.) Fondation Nationale de Transfusion Sanguine, Les Ulis, France pp. 243-247.
de Leij et al. (1990) in Bispecific Antibodies and Targeted Cellular Cytoxicity (Romet-Lemonne et al., eds.) Foundation Nationale de Transfusion Sanguine, Les Ulis, France pp. 249-253.
Nitta et al. (Feb. 17, 1990) The Lancet pp. 368-371.
Ball et al. (1992) J. Hematotherapy 1:85-94.
Shen, Li et al. J. Immunol. 137(11):3378-3382 (1986).
Anderson, C.L. et al. Fed. Proc. 45:714 (1986).
Liu, M.A. et al., Proc. Nat'l. Acad. Sci. USA 82:8648-8654 (198.
Hoffman, R.W. et al., J. Immunol. 135:5-7 (1985).
Langlois, A.J. et al., J. Immunol. 126:5 (1981).
Shen, L. et al., Mol. Immunol. 21:167-173 (1984).
Guyre, P.M. et al., J. Clin. Invest. 72:393-397 (1983).
Looney et al., (1986) J. Immunol. 136: 1641-1647.
Karpovsky B. et al., J. Exp. Med. 160:1686-1701 (1984).
Perez, P. et al., Nature 316:354 (1985).
Seaver, Genetic Engineering News. vol. 14, pp. 10 & 21, 1994.
Schlom, pp. 95-134 in Broder, "Molecular Foundations of Biology", Williams & Wilkins, 1991.
Waldmann, Science 252: 1657-1662, 1991.
Andrews et al. Blood 68:1030-1035, 1986.
Cuttitla et al. PNAS USA 78: 4591-4595, 1981.
Dillman, Annals Internal Med. 111:592-603, 1989.
Hird et al. In: "Genes and Cancer", Carney et al. Eds John Wiley & Sons 1990, pp. 183-189.
Brennan et al. Science 229:81-83, 1985.
Lubeck et al, J.Immunol., 135(2), 1299, (1985).
Harris et al. Tibtech 11:42-44.
Anderson Clark L.
Fanger Michael W.
Guyre Paul M.
Arnold, Esq. Beth A.
DeConti, Jr. Esq. Giulio A.
Hutzell Paula K.
Trustees of Dartmouth College
LandOfFree
Bifunctional and heteroantibodies specific for the high affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifunctional and heteroantibodies specific for the high affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional and heteroantibodies specific for the high affinity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-392508